Replies to post #72852 on Biotech Values

[DewDiligence]

IDIX ReadMeFirst

[Added “The New Battle Lines in HIV” and reorganized the
sections to emphasize that IDIX is now primarily an HCV company.]


What is IDIX’s business all about?
#msg-35432611 What’s up with IDIX?
#msg-31943984 IDIX’s drug portfolio
#msg-26915744 Addressable markets for antiviral drugs


Valuation and finances
#msg-35393182 Cash balance is about $75M
#msg-33234317 3Q08 financial results
#msg-35242833 Table of recent biotech buyouts


News flow
#msg-35392447 2009 clinical goals


Officers, directors, and major shareholders
#msg-33971771 Composition of Board of Directors
Capsule résumés of executive officers (click on a name)
#msg-33807169 Largest shareholders
#msg-33807081 Latest NVS “true up” purchase
#msg-33625817 NVS’ cost basis
#msg-29157548 Standstill agreement with NVS has expired
#msg-33972221 Current insider shareholdings
#msg-32238060 Recent insider transactions


HCV program: Economic rationale
#msg-29018192 Prevalence and incidence of HCV in the US
#msg-26915744 Estimated size of worldwide market
#msg-30190435 Devastating risk of undertreating HCV
#msg-34694166 US prevalence of genotypes 1a and 1b


HCV program: IDX184
#msg-26915921 Why IDX184 is better than NM283
#msg-34771363 Nucleoside vs nucleotide
#msg-34763865 IDX184 begins phase-1/2 monotherapy study
#msg-28715477 IDX184 preclinical data
#msg-35392447 2009 clinical goals


HCV program: IDX375 and IDX136/316
#msg-31043481 Introducing IDX136, IDX316, and IDX375
#msg-34334563 Blurb on IDX375 from hivandhepatitis.com
#msg-34677952 Comments on the non-nucleoside “class”
#msg-35392447 2009 clinical goals


HCV program: Competition
#msg-34770929 HCV: Most Likely to Succeed (IMHO)
#msg-34772664 Role of interferon in future combination therapy


HIV program
#msg-35391933 IDIX inks worldwide partnership with GSK
#msg-35447718 The New Battle Lines in HIV
#msg-32355170 HIV market overview (detailed)
#msg-24673329 HIV market overview (for dummies)
#msg-31175781 HIV incidence in US is higher than previously thought
#msg-35109525 Sustiva sells $1.2B/yr
#msg-31419107 Increased HIV screening will expand market
#msg-33124429 New guidelines to recommend earlier treatment
#msg-33898893 Half of untreated US carriers are in 350-500 CD4 range
#msg-29985830 Design of a late-stage HIV trial


HBV program
#msg-32683976 Estimated royalty income from NVS
#msg-23785846 Status of Sebivo launch in EU
#msg-23434932 Treating asymptomatic e- patients will boost market
#msg-11099728 US Asian immigrants largely untreated
#msg-32945811 Viread alters competitive landscape (1)
#msg-33257652 Viread alters competitive landscape (2)
#msg-33901499 Musings on HBV combination therapy


Reference links
http://www.idenix.com/hiv/about
http://www.aidsmeds.com/list.shtml
http://www.idenix.com/hepc/about
http://www.hcvdrugs.com/
http://www.hivandhepatitis.com
http://www.cdc.gov/ncidod/diseases/hepatitis/b/fact.htm
http://www.who.int/mediacentre/factsheets/fs204/en
http://www.idenix.com/about/media/Glossary_of_terms.pdf